171 related articles for article (PubMed ID: 19578773)
1. Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
Fuzio P; Lucarelli G; Perlino E; Battaglia M; Bettocchi C; Selvaggi FP; Ditonno P
Oncol Rep; 2009 Aug; 22(2):327-35. PubMed ID: 19578773
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer.
Fuzio P; Ditonno P; Lucarelli G; Battaglia M; Bettocchi C; Senia T; Perlino E
Int J Oncol; 2011 Nov; 39(5):1233-42. PubMed ID: 21785821
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the beta1C integrin splice variant in human prostate adenocarcinoma.
Moro L; Greco M; Ditonno P; Battaglia M; Marra E; Perlino E
Int J Oncol; 2003 Dec; 23(6):1601-6. PubMed ID: 14612932
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of beta1 integrin expression in the physio/pathological states of human endometrial tissues.
Moro L; Greco M; Maiorano E; Selvaggi L; Marra E; Perlino E
Int J Oncol; 2005 Feb; 26(2):457-65. PubMed ID: 15645131
[TBL] [Abstract][Full Text] [Related]
5. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
[TBL] [Abstract][Full Text] [Related]
6. Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment.
Goel HL; Moro L; King M; Teider N; Centrella M; McCarthy TL; Holgado-Madruga M; Wong AJ; Marra E; Languino LR
Cancer Res; 2006 Jan; 66(1):331-42. PubMed ID: 16397247
[TBL] [Abstract][Full Text] [Related]
7. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
9. Regulation of TGF-β1 expression by androgen deprivation therapy of prostate cancer.
Fuzio P; Ditonno P; Rutigliano M; Battaglia M; Bettocchi C; Loverre A; Grandaliano G; Perlino E
Cancer Lett; 2012 May; 318(2):135-44. PubMed ID: 22269108
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K
Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984
[TBL] [Abstract][Full Text] [Related]
11. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma.
Perlino E; Lovecchio M; Vacca RA; Fornaro M; Moro L; Ditonno P; Battaglia M; Selvaggi FP; Mastropasqua MG; Bufo P; Languino LR
Am J Pathol; 2000 Nov; 157(5):1727-34. PubMed ID: 11073831
[TBL] [Abstract][Full Text] [Related]
12. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
13. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Dahlman A; Edsjö A; Halldén C; Persson JL; Fine SW; Lilja H; Gerald W; Bjartell A
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):369-75. PubMed ID: 20680031
[TBL] [Abstract][Full Text] [Related]
14. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
15. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
16. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
20. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
